Rivaroxaban (Xarelto ) - Reminder That 15 MG and 20 MG Tablets Should Be Taken With Food - GOV - UK
Rivaroxaban (Xarelto ) - Reminder That 15 MG and 20 MG Tablets Should Be Taken With Food - GOV - UK
Rivaroxaban (Xarelto ) - Reminder That 15 MG and 20 MG Tablets Should Be Taken With Food - GOV - UK
UK
GOV.UK
1. Home (https://www.gov.uk/)
2. Drug Safety Update (https://www.gov.uk/drug-safety-update)
From:
Medicines and Healthcare products Regulatory Agency (https://www.gov.uk/government/organisations/medicines-
and-healthcare-products-regulatory-agency)
Therapeutic area:
Cardiovascular disease and lipidology (https://www.gov.uk/drug-safety-update?
therapeutic_area%5B%5D=cardiovascular-disease-lipidology), Haematology (https://www.gov.uk/drug-safety-update?
therapeutic_area%5B%5D=haematology)
Contents
Importance of taking rivaroxaban 15 mg and 20 mg tablets with food
Further information about rivaroxaban
https://www.gov.uk/drug-safety-update/rivaroxaban-xarelto-reminder-that-15-mg-and-20-mg-tablets-should-be-taken-with-food 1/2
18/7/2019 Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food - GOV.UK
MHRA has received a small number of reports of patients taking rivaroxaban 15 mg or 20 mg who experienced a
thromboembolic event, which the reporter suspected was due to the patient taking the tablets on an empty
stomach.
The section of the Patient Information Leaflet for rivaroxaban 15 mg and 20 mg tablets that advises patients how
to take their medicine has been revised to emphasise patients must take rivaroxaban with a meal and the tablets
should be swallowed preferably with water.
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for
prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with
elevated cardiac biomarkers (2.5 mg dose)
Co-administered with ASA, for the prevention of atherothrombotic events in adult patients with coronary
artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events (2.5
mg)
Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement
surgery (10 mg)
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or
more risk factors, such as congestive heart failure, hypertension, age of 75 years and older, diabetes
mellitus, prior stroke or transient ischaemic attack (15 mg and 20 mg)
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT
and PE in adults (10 mg, 15 mg, and 20 mg).
Article citation: Drug Safety Update volume 12, issue 12: July 2019: 3.
https://www.gov.uk/drug-safety-update/rivaroxaban-xarelto-reminder-that-15-mg-and-20-mg-tablets-should-be-taken-with-food 2/2